Skip to main content
Explore URMC
menu

Jeremiah E. Moore, PharmD, BCOP

(Pronouns: he/him/his)

Contact Information

Biography

Professional Background

Jeremiah Moore, PharmD, BCOP, earned his bachelor of science degree from the State University of New York College of Environmental Science and Forestry and his doctor of pharmacy degree from the St. John Fisher College Wegmans School of Pharmacy.

He began his career at the University of Rochester Medical Center in 2010 as a clinical staff pharmacist and has served as a clinical pharmacist specialist since 2014. Moore is board certified in oncology pharmacy and serves as a clinical preceptor for the outpatient ambulatory hematology/oncology rotations for PGY1 and PGY2 pharmacy residents. He serves as an adjunct professor at the St. John Fisher College Wegmans School of Pharmacy as well as a preceptor for APPE students. In addition, he is an active member of the Hematology/Oncology Pharmacy Association (HOPA). Clinical interests include clinical research in hematological malignancies.

Credentials

Education

2003
Bachelor of Science | State University of New York College of Environmental Science and Forestry

2010
Doctor of Pharmacy | St. John Fisher College Wegmans School of Pharmacy
Pharmacy

Awards

2018
University of Rochester Medical Center Outstanding Team
Sponsor: URMC 5th Annual Institute for Innovative Education Team Based Ca

2018
HOPA Hill Day Travel Grant Recipient
Sponsor: Hematology/Oncology Pharmacy Association

2015
Preceptor of the Year Nominee
Sponsor: St. John Fisher College Wegmans School of Pharmacy

2014
University of Rochester Team Excellence Award
Sponsor: URMC Board of Directors

VIEW ALL expand_more

Publications

Journal Articles

2/4/2021
Moore JE, Delibert K, Baran AM, Evans AG, Liesveld JL, Zent CS. "Targeted therapy for treatment of patients with classical hairy cell leukemia." Leukemia research.. 2021 Feb 4; 102:106522. Epub 2021 Feb 04.

1/17/2020
Moore J, Baran AM, Meacham PJ, Evans AG, Barr PM, Zent CS. "Initial treatment of B-cell prolymphocytic leukemia with ibrutinib." American journal of hematology.. 2020 Jan 17; Epub 2020 Jan 17.

10/17/2019
Williams AM, Baran AM, Schaffer M, Bushart J, Rich L, Moore J, Barr PM, Zent CS. "Significant weight gain in CLL patients treated with Ibrutinib: A potentially deleterious consequence of therapy." American journal of hematology.. 2019 Oct 17; Epub 2019 Oct 17.

VIEW ALL PUBLICATIONS